RA'ANANA, Israel, Sept. 24,
2024 /PRNewswire/ -- Inspira™ Technologies OXY
B.H.N. Ltd. (Nasdaq: IINN, IINNW), ("Inspira Technologies",
"Inspira", or the "Company") a breakthrough medical technology
company, is poised to make a significant impact at the 34th Annual
Extracorporeal Life Support Organization (ELSO) Conference in
Detroit, Michigan, on the
29th to the 30th of September 2024. The Company will be presenting
its latest and future technologies, underscoring its commitment to
innovation and excellence in the field of extracorporeal blood
circulation technologies.
During the conference, attendees will have the opportunity to
engage in interactive demonstrations and presentations, giving
physicians and perfusionists a hands-on experience of the Company's
latest innovations, highlighting key design features and advantages
of the U.S. Food & Drug Administration-cleared INSPIRA™ ART100
system to be deployed to the U.S. market. The U.S sales team and
the VP of Product, Mr. Tomer Carmeli
together with the company's team of professionals, including our
Medical Director, Dr. Dekel Stavi,
MD and our CTO, Dr. Daniella Yeheskely-Hayon PhD, will be available
to address questions and discuss the potential impact of these
innovations on patient care.
Join us at booth #18 to see the INSPIRA™ ART100 system and to
meet in person with the Inspira U.S. local sales team, led by
Glo-Med Networks Inc. ("Glo-Med"), Inspira's chief distributor,
head of sales and after-market service provider in the U.S., which
will support the U.S. rollout, ensuring that leading hospitals and
medical centers have immediate access to this breakthrough
technology.
About ELSO
The Extracorporeal Life Support Organization (ELSO) is an
international nonprofit consortium of healthcare institutions,
researchers, and industry partners. The organization provides
support to those delivering extracorporeal life support through
continuing education, guidelines, original research, publications,
and a comprehensive registry of extracorporeal membrane oxygenation
(ECMO) patient data. ECMO clinicians, research scientists, and
members of regulatory and public health institutions are eligible
for membership in ELSO. There are currently over 20,000 users and
center members from over 50 countries. Memberships allows
physicians, nurses, perfusionists, respiratory therapists,
researchers and other healthcare professionals to become more
directly involved in the world's largest ECMO community.
Inspira Technologies OXY B.H.N. Ltd.
Inspira™ Technologies is an innovative medical technology
company in the respiratory treatment arena. The Company has
developed a breakthrough Augmented Respiration Technology (INSPIRA™
ART), with adaptive blood monitoring and blood oxygenation
technology designed to rebalance patient oxygen saturation levels.
This technology potentially allows patients to remain awake during
treatment while reducing the need for highly invasive, risky, and
costly mechanical ventilation systems that require intubation and
medically induced coma. Equipped with HYLA™ real-time continuous
blood monitoring technology, the system instantly detects changes
in patient conditions, empowering physicians in making informed
decisions.
The Company's INSPIRA™ ART100 system has obtained FDA 510(k)
clearance for use in Cardiopulmonary Bypass procedures, along with
the Israeli AMAR certification for both Extra-Corporeal Membrane
Oxygenation and Cardiopulmonary Bypass procedures.
The Company's other products, including the INSPIRA™ ART also
known as the INSPIRA™ ART500 or Gen 2, the INSPIRA™ Cardi-ART
portable modular device and HYLA™ blood sensor, are currently being
designed and developed, and have not yet been tested or used in
humans and have not been approved by any regulatory entity.
For more information, please visit our corporate website:
https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking
statements pursuant to U.S. Federal securities laws. These
forward-looking statements and their implications are based on the
current expectations of the management of the Company only and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses the upcoming ELSO
conference and the potential benefits of its products. These
forward-looking statements and their implications are based solely
on the current expectations of the Company's management and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. Except as otherwise required by law,
the Company undertakes no obligation to publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. More detailed information about the risks and
uncertainties affecting the Company is contained under the heading
"Risk Factors" in the Company's annual report on Form 20-F for the
fiscal year ended December 31, 2023
filed with the U.S. Securities and Exchange Commission (the "SEC"),
which is available on the SEC's website, www.sec.gov
For more details:
Inspira Technologies – Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485
Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD., All
rights reserved.
Logo -
https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/inspira-launches-inspira-art100-at-the-worlds-largest-extracorporeal-life-support-conference-302257031.html
SOURCE Inspira Technologies
